• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Long-term outcome of juvenile dermatomyositis rests on early treatment with immunosuppresants


Washington -Timely diagnosis of juvenile dermatomyositis is critical because early, aggressive management with immunosuppressive agents, even for patients with amyopathic disease, is the best method for preventing calcinosis, which is a source of significant morbidity for these children, said Amy S. Paller, M.D., at the annual meeting of the American Academy of Dermatology.

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.